Callitas Health Inc, formerly M Pharmaceutical Inc, is a Canada-based biomedical technology company. The Company is engaged in developing and commercializing drug treatments and biomedical technologies for the treatment of obesity and weight loss. The Company's biomedical technologies include Trimeo, Trimtec and eMosquito. Trimeo capsules are temporary controllable pseudobezoars for non-invasive gastric volume reduction for the treatment of obesity; Trimtec are gastrointestinal neurostimulators implanted laparoscopically for the treatment of obesity and gastroparesis without permanent anatomical modification of the stomach, and eMosquito wearable blood monitor, for automatic and autonomous monitoring of blood glucose by diabetics. The Company has entered into agreement from Chelatexx, LLC (Chelatexx) related to a reformulated orlistat for weight loss. The Company also focuses on developing C-103.